Showing 7181-7190 of 8881 results for "".
- Scleroderma Foundation to Honor Genentech's Dr. Jeffrey Siegel for Scientific Contributionshttps://practicaldermatology.com/news/scleroderma-foundation-to-honor-genentechs-dr-jeffrey-siegel-for-scientific-contributions/2458864/Dr. Jeffrey Siegel, Senior Group Medical Director of Immunology at Genentech, will be honored by the Scleroderma Foundation of Southern California with the Spirit of Leadership Award at their 17th annual “Key to a Cure” gala, which will be held on Saturday, Octobe
- The Osteopathic Dermatologist: Dr. Peter Ilowite Shares His Crafthttps://practicaldermatology.com/news/the-osteopathic-dermatologist-dr-peter-ilowite-shares-his-craft/2458866/Peter Ilowite, DO, Assistant Professor of Dermatology at Mt. Sinai Hospital and Dermatology Residency and an Assistant Professor of Medicine at Touro College of Osteopathic Medicine, both of New York City, spoke at the Atlantic Regional Osteopathic Convention (AROC
- 100,000 Join the ASPIRE Galderma Rewards Loyalty Program in First 90 dayshttps://practicaldermatology.com/news/100000-join-the-aspire-galderma-rewards-loyalty-program-in-the-first-90-days/2458867/Galderma’s ASPIRE Rewards program has enrolled 100,000 consumers since its launch on May 1, 2015. ASPIRE Galderma Rewards is a new loyalty program connecting US consumers and healthcare professionals using the Galderma family of aesthetic products. The vision of the Galderma a
- Ferndale Healthcare Launches Vegetarian Formula of Heliocarehttps://practicaldermatology.com/news/ferndale-healthcare-launches-vegetarian-formula-of-heliocare/2458868/Ferndale Healthcare® has introduced to its existing Heliocare® line a new vegetarian formula, free of gluten and artificial dyes. The new Heliocare® Ultra Dietary Supplement contains a powerful blend of antioxidants, including Fernblock®
- FDA Approves Humira for Moderate to Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-approves-humira-for-moderate-to-severe-hidradenitis-suppurativa/2458873/The FDA approved AbbVie’s HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HUMIRA is now the first and only FDA-approved therapy for adults with HS. Earlier this year, the FDA granted HUMIRA orphan drug designation for t
- Solta Medical Launches Clear + Brilliant pelo for Laser Hair Removalhttps://practicaldermatology.com/news/solta-medical-launches-clear-brilliant-pelo-for-laser-hair-removal/2458875/Solta Medical, a division of Valeant Pharmaceuticals North America LLC launched its Clear + Brilliant pelo™ laser for permanent hair reduction. The US launch of this device, which joins Solta Medical's aesthetic device portfolio, follows a unique partnership with German Medical
- Suneva Medical: Bellafill Study is Largest, Longest Post-market Clinical Evaluation of Dermal Fillerhttps://practicaldermatology.com/news/suneva-medical-bellafill-study-is-largest-longest-post-market-clinical-evaluation-of-dermal-filler/2458874/Billed as the largest and longest post-market clinical evaluation of a dermal filler, a new study reported by Suneva Medical shows high levels of patient satisfaction and favorable safety outcomes with Bellafill five-years post-treatment. With an 87 percent retention rate, the study showed that a
- Alphaeon Launches Social Commerce Store for Physician Specialistshttps://practicaldermatology.com/news/alphaeon-launches-social-commerce-store-for-physician-specialists/2458876/ALPHAEON Corporation launched ShoutMD 3.0. ShoutMD is a unique professional and social network that allows board certified physician specialists to share insights, start discussions, and collaborate with their peers with the goal of improving patient experiences and outcomes, according to the com
- Cynosure to Host Investor Event to Introduce SculpSurehttps://practicaldermatology.com/news/cynosure-to-host-investor-event-to-introduce-sculpsure/2458877/Cynosure, Inc. will host an investor event in New York City on Tuesday, September 15 to introduce SculpSure™, the only FDA-cleared hyperthermic laser treatment for non-invasive fat reduction. The Company will provide a live webcast of the event presentations from approximately 10:00 a.m. to
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).